Abstract The ability to generate human induced pluripotent stem cells (iPSCs) has opened new avenues for human disease modelling and therapy. The aim of our study was to determine research participants' understanding of the information given when donating skin biopsies for the generation of patient-specific iPSCs. A customised 35-item questionnaire based on previous iPSC consent guidelines was sent to participants who had previously donated samples for iPSC research. The questionnaire asked pertinent demographic details, participants' motivation to take part in iPSC research and their attitudes towards related ethical issues. 234 participants were contacted with 141 (60.3 %) complete responses received. The median duration between recruitment and follow-up questioning was 313 days (range 10-573 days). The majority of participants (n = 129, 91.5 %) believed they understood what a stem cell was; however, only 22 (16.1 %) correctly answered questions related to basic stem cell properties. We found no statistically significant difference in responses from participants with different levels of education, or those with a health sciences background. The poor understanding amongst participants of iPSC research is unlikely to be unique to our study and may impact future research if not improved. As such, there is a need to develop an easily Alice Pébay and Alex W. Hewitt have jointly supervised this work.
Introduction
The derivation of human induced pluripotent stem cells (iPSCs) is enabling extensive progress in disease modelling and cell-based therapies (Park et al. 2008; Takahashi et al. 2007; Yu et al. 2007) . Given that these cells can be derived from almost any individual without the use of embryonic tissue, they are thought of as an ethical alternative to human embryonic stem cells. Nonetheless, unique ethical issues arise from the use of iPSCs, such as the sharing of samples with external investigators or pharmaceutical companies; the generation of chimeric animals; future uses of cells beyond that outlined in the consent process; and financial gains from commercialization of individual samples. As the now infamous case involving Henrietta Lacks demonstrated (McCarthy 2013) , it is crucial to ensure research participants give informed consent and understand the broad and specific implications of their involvement.
Although ongoing breakthroughs in disease modelling and therapy will be achieved using iPSCs (Kobold et al. 2015) , it is becoming increasingly clear that to facilitate such research, samples from a large number of participants will be required (Rouhani et al. 2014) . While the donation of cells to derive iPSCs does not raise any specific ethical questions itself, important issues relating to the applications of samples must be communicated to participants. These relate to immortalisation of cell lines, participant privacy, sharing of biospecimens, reproductive research, and animal experimentation (Aalto-Setala et al. 2009 ). With informed consent guidelines and recommendations in iPSC research well established (Aalto-Setala et al. 2009; Lomax et al. 2015; Lowenthal et al. 2012) and research confirming that these issues are important to the general public (Dasgupta et al. 2014) , there is a pressing need to determine the efficacy of current consent procedures.
Previous studies suggest that consent understanding and recall is generally poor amongst study participants in medical research (Khan et al. 2014) ; however, it is unclear whether this is the case for informed consent involving iPSCs. To date, our research group has collected a large repository of biospecimens for iPSC research. Therefore, the aim of this study was to investigate the informed consent recall and understanding of these participants. Furthermore, we sought to determine what demographic and personal factors affected consent recall. We also explored participants' primary motivation for volunteering to provide a sample for this iPSC research, and their perception of the applications of stem cell technology.
Materials and methods

Study design and participant recruitment
Ethics approval was obtained from the Royal Victorian Eye and Ear Hospital Human Research and Ethics Committee (RVEEH HREC-11/1031H) and the Monash University Human Research Ethics Committee (MUHREC-CF15/1206). For the purpose of this study, we investigated the informed consent recall and understanding of participants who had previously provided a skin biopsy to our research facility between May 2013 and April 2015. iPSC samples were collected primarily for ophthalmic research purposes and included both those taken from normal controls as well as patients diagnosed with inherited eye conditions.
Prior to their participation in ophthalmic iPSC research, all participants were provided an information sheet and brochure outlining key aspects of the research (Supplementary Items 1 and 2), a consent form as well as a revocation of consent form (available on request). At the time of their specimen collection, participants underwent an informed consent procedure based upon the work of Aalto-Setälä and colleagues (Aalto-Setala et al. 2009 
Data collection
A 35-item questionnaire was designed to assess participants' understanding of the consent process, motivation to partake in research, and attitude towards ethical issues associated with the research (Supplemental Item 3). This questionnaire was based on the participant information sheet given at the time of their original consent, as well as previously published focus group discussion and iPSC consent guidelines (Dasgupta et al. 2014; Lowenthal et al. 2012) .
The customised questionnaire comprised four sections. The first section recorded demographic information, including age, gender, religion and level of education. Furthermore, to assess participants' personal investment in the research, they were asked whether they or a family member were affected with an ophthalmic condition relevant to the research. The second section asked specific details about the consent process undertaken on the day of their specimen collection. This included their motivation for participating; whether they had read the information sheet and in how much detail; their perceived understanding of the consent information; the most useful source of information; and the details of any supplementary information they accessed outside of what was given by the research team.
Section three allowed participants to rate their general attitudes and understanding of stem cell research on nine questions using a four-point Likert scale ranging from 'Strongly Agree' to 'Strongly Disagree'. An 'I don't know' option was also provided. These questions asked for participants' specific attitudes towards embryonic stem cell research; reproductive cloning from stem cells; and research which could lead to cell replacement therapy. Three questions from section three assessed participants' knowledge of key points in the consent process including expectation of financial or personal benefit and the ability to withdraw from research.
The fourth section included eleven questions with the options of 'True', 'False' or 'Unsure' and further assessed participants' understanding and recall of the actual consent procedure itself. Questions included in this section tested basic knowledge of stem cells, such as their indefinite lifespan and their ability to differentiate into other tissues in the body; whether their sample may lead to cell replacement therapy or used for reproductive cloning, when it is used to generate gametes; sharing of samples with other scientists; whether their sample could be injected into other people; use of animals in experiments; and pharmaceutical company involvement in research. Finally, participants were given the option to comment on how the team could improve the consent process.
To refine the questionnaire, a Thinking-Aloud Cognitive Testing method was applied (Collins 2003) . Five participants were successively interviewed with Cognitive Testing to assess their understanding and interpretation of each question. The questionnaire was updated following each interview, and the wording and format of five questions were changed, with no updates deemed necessary after the final two interviews. Readability analysis (Table 1) found that the final questionnaire had a Gunning Fog Score of 7.7 (www.readability-score.com accessed 4 May 2015), which suggests our questionnaire should have been understandable by all participants.
Participants were administered the final questionnaire either electronically by email or via a hardcopy sent to their last known postal address. A hardcopy of the questionnaire was also posted to participants who did not respond to the email within 2 weeks.
Data analysis
Understanding of consent information was gauged by results from fourteen questions in the last two sections of the questionnaire. For the final section's dependent variables, we collapsed the five-point Likert scale to a three-point scale (''disagree'', ''neutral'', ''agree'') merging the ''strongly agree'' and ''agree'' options and the ''strongly disagree'' and ''disagree'' options. Questions gauging comprehension were labelled as 'correct' or 'incorrect' depending on the appropriate answer to each question. For quantitative analysis, 'unsure' and 'I don't know' answers were grouped in the 'incorrect' category.
Data were processed using Statistical Package for the Social Sciences, IBM (version 23.0; SPSS Inc., Chicago, IL, USA). Associations between consent recall and variables such as time since consent and skin sample collection, level of education, family history of genetic disease or medical condition, a background in health sciences, perceived understanding of consent and accessing additional sources of information about the study were calculated using the Pearson Chi Squared Test. Attitudes towards applications of stem cell research were compared to variables such as religious affiliation and a personal or family history of genetic disease. Results were considered significant at p \ 0.05.
Results
A total of 234 participants who had previously donated a skin biopsy were contacted for the current study. Each was sent a questionnaire. 153 (65.4 %) responses were received, and of these, 141 (92.2 %) had completed at least the first two sections in full and therefore were included in the analysis. The median duration between skin biopsy and follow-up questioning was 313 days (range 10-573 days), whilst the selfreported median time since biopsy was 365 days (range 10-1095 days). Table 2 displays the demographic details of respondents. One hundred and three (73.0 %) participants did not access any additional information prior to providing a skin biopsy for iPSC research, and 88 (85.4 %) stated that this was because of trust in the research team. When questioned about the most useful source of information, 80 (57.6 %) participants stated speaking to the research team on the day of sample collection, whilst 55 (39.6 %) reported that the information sheet was most beneficial. 115 (81.6 %) participants stated that they had read the entire information pamphlet at least once.
A total of 132 (93.6 %) participants reported feeling adequately informed following the consent process and 136 (97.8 %) participants felt able to ask questions. A large proportion (129, 91.5 %) of subjects believed they understood what is meant by the term ''stem cell''; however, only 22 (16.1 %) people knew that their sample could be maintained indefinitely and 71 (51.8 %) understood that it could be differentiated into any other cell in the adult body (Fig. 1) . Participants reported understanding of the term ''stem cell'', yet this was not associated with their comprehension of sample immortality or pluripotency (p [ 0.05).
Demographic factors such as level of education, background in health science or being personally affected by an ophthalmic disease were not associated with the number of correct responses (p [ 0.05). Additionally, time since skin biopsy was not associated with consent recall or understanding about stem cell biology (p [ 0.05). 104 (75.9 %) respondents were aware that their samples would be used to help develop new treatments and tests, but only 41 (29.9 %) appreciated that pharmaceutical companies could be involved in this process. Only 25 (18.2 %) people were aware of specific aspects explicitly stated in the participant information sheet, such as the fact that animals may be used in the research.
The overall motivation to participate appeared to be generally altruistic, with 131 (92.9 %) people stating that contributing to medical research and the community was their primary reason for participating. Furthermore, 118 (84.9 %) participants stated they did not expect to financially benefit from any discoveries; however, 66 (47.5 %) participants reported that they were hoping to personally benefit from the study. Being personally affected by an inherited disease was not significantly associated with the support of embryonic stem cell research (p [ 0.05).
Almost all participants (137, 98.6 %) supported cell replacement therapy, with 113 (81.3 %) supporting the research use of embryos derived from IVF samples and 43 (30.9 %) supporting reproductive cloning. Overall, having a religious affiliation was not significantly associated with acceptance of these applications. However, subgroup analysis confirmed that people with a Catholic faith had less support for embryonic stem cell research (p = 0.005) and research involving reproductive cloning (p = 0.047).
Discussion
With ongoing iPSC-related research, the number of people providing samples is steadily increasing. As such, it is important to ensure that iPSC consent procedures are both comprehensive and easily understandable. Our study suggests there is generally a poor level of understanding surrounding iPSC consent information amongst iPSC study participants. These findings support previously published work regarding understanding of informed consent in research (Khan et al. 2014; Robinson et al. 2013; Tam et al. 2015) and other areas of medicine, including prescription of medication, preoperative surgical information and emergency treatment (Dathatri et al. 2014; Glicksman et al. 2014; Li et al. 2014) . Our study highlighted a marked discordance between perceived understanding, and actual understanding of the information provided during the informed consent process, with participants generally overestimating their knowledge regarding stem cells. Other studies have reported a similar disconnect between perceived and actual understanding (Sepucha et al. 2010) ; however, this is not consistent throughout the literature with studies showing that satisfaction with the consent process may be a predictor of better recall (Johnson et al. 2011) . It has been reported that high levels of trust in the study team increase participants' perceived level of understanding (Sepucha et al. 2010) , and this could potentially account for our observations. Despite almost all respondents in this study reporting they felt able to ask questions, it would appear that they do not take this opportunity to explore important issues when they believe they are already well informed.
In contrast to other work (Ahsanuddin et al. 2015; Crepeau et al. 2011; Fink et al. 2010) , no single demographic factor was significantly associated with consent understanding or recall in our current study. This may indicate that iPSC consent understanding is more dependent on the consent process than individual participant factors; however, further research using a longitudinal study design is required to establish causation. It could also reflect the fact that our study population was relatively homogenous. Interestingly, we found that the majority of respondents did not access any information beyond what was provided during the consent process. This underscores the importance of detailed, yet comprehensible consent procedures.
We found that participants with moral objections to issues such as reproductive cloning performed better when tested on this in the comprehension section of our questionnaire. This may indicate that these individuals are likely to be engaged during the consent process in issues they feel strongly about. Given the traditional resistance of the Catholic church towards some aspects of reproductive medicine, it was not surprising that people with such a religious affiliation reported less support for IVF embryonic stem cell research and reproductive therapy than those of any other faith. In contrast, there was universal acceptance of cell replacement therapy, highlighting the wide public acceptance of this application of research, and alleviating some concerns that people may be resistant to donating cells that will become an integral part of another human (Aalto-Setala et al. 2009 ).
Obtaining informed consent is crucial in any research involving human volunteers (World Medical Association 2013) and although all samples were wilfully provided, there would appear to be great room to improve the consent understanding of iPSC study participants. Key issues raised by experts in the field such as immortalisation of cell lines, sharing of biospecimens and animal experimentation were some of the least understood areas of consent. These findings may partly be due to the length of time between participation and the follow-up questionnaire, with studies showing that consent recall decreases with time (Lavelle-Jones et al. 1993) . Importantly however, we found that people who completed the questionnaire within 6 months of skin biopsy did not appear to have a significantly greater recall or understanding of this work. Given the indefinite nature of individual samples, it is important that consent recall does not lapse dramatically. The potential to recontact participants has been raised by a number of researchers, particularly if samples are used for applications not addressed in the original consent process (Aalto-Setala et al. 2009; Lowenthal et al. 2012) . The poor recall we have found may indicate a need to revisit consent at particular times if samples will be used into the future. Further research is required to establish whether participants are interested in being reminded of key points of their consent, as well as updates in the precise applications of their samples.
There may have been considerable recall bias due to the retrospective nature of our study. Additionally, it is important to note the differences in demographic details between people who participated in this ancillary study versus those who did not, suggesting some response bias (Table 2) . Furthermore, a single study population is unlikely to be completely representative of all iPSC research participants; however, we feel that our results would be reflected in other large-scale iPSC projects. Nonetheless, despite our consent procedures being based on published guidelines (Aalto-Setala et al. 2009; Dasgupta et al. 2014; Lowenthal et al. 2012) , our protocols may not directly mirror other researchers' procedures, and therefore findings may differ in other studies. Finally, further research will be required to determine whether the poor comprehension demonstrated is truly a lack of understanding or simply an ambivalence to these issues by the donors.
Despite the fact that information relevant for ensuring adequate iPSC informed consent has been explored in great detail (Aalto-Setala et al. 2009; Dasgupta et al. 2014; Lowenthal et al. 2012) , our results suggest that this information is not being well absorbed by study participants. These findings have important implications on effective communication in iPSC informed consent. Indicating that the timeintensive production of written consent information is not achieving desired levels of participant understanding. With ongoing breakthroughs in stem cell science and molecular techniques, researchers must ensure that future progress is not hindered by inadequate informed consent obtained whilst a biomedical technology is in a nascent stage. Alarmingly, it would appear that participants do not understand aspects of iPSC research despite a perceived belief that they are well informed. Ongoing work, investigating improved methods for communicating all aspects of iPSC research to participants, is clearly required.
